Regencell Bioscience Holdings Limited Research and Development Expense
Regencell Bioscience Holdings Limited (RGC) reported Research and Development Expense of $948.29 thousand for the 12-month period ending 2025-06-30, per its 20-F filed 2025-10-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-10-31
| Period end | Research and Development Expense 12 month |
|---|---|
| 2025-06-30 | $948.29K 20-F · filed 2025-10-31 |
| 2024-06-30 | $1.07M 20-F · filed 2025-10-31 |
| 2023-06-30 | $1.58M 20-F · filed 2025-10-31 |
| 2022-06-30 | $2.51M 20-F · filed 2024-10-25 |
| 2021-06-30 | $438.32K 20-F · filed 2023-10-27 |
| 2020-06-30 | $386.23K 20-F · filed 2022-10-31 |
| 2019-06-30 | $228.22K 20-F · filed 2021-10-29 |